⏳
Lower Competition & Faster Trials
Compared to other regions, Europe offers a landscape with lower competition for trial sites and patient recruitment. This advantage allows for quicker trial setups, shorter timelines, and smoother processes, giving your study a faster path from initiation to results.
⚙️
Strategic Optimization
Conducting a clinical trial in Europe offers an opportunity for strategic optimization, starting with the potential for a swift FPI within just three months. This speed, combined with country-specific recruitment strategies tailored to boost recruitment rates, accelerates trial progress. To maximize your recruitment strategy and also your relations with KOL, combining your EU study with a small pool of patients in the US will guarantee FDA validation, Investigators' interests, and, ultimately, Stakeholders' satisfaction.
💵
Cost Efficiency
Conducting trials in Europe can significantly reduce costs, offering high-quality results without the financial strain. Lower operational expenses - 40% on average, combined with an efficient regulatory environment, make Europe an attractive option for companies looking to maximize their budget without sacrificing standards.
Additional Benefits
Patient perspective
Eager to participate in trials
High recruitment rate
Large population of treatment naïve
Investigator perspective
Motivated, experienced & GCP trained investigators
Lower number of clinical trials
Regulation overview
Harmonized CTIS regulation
Access to non-European countries with fast regulatory approval (usually 2 months)
Quality
High level quality of trials (proven by FDA)
Collection of superior quality data
Competitive study start-up & recruitment times
Any trial conducted in Europe can be designed with FDA-ready datasets using CDISC standards, including ADaM, ensuring that all results meet FDA compliance requirements seamlessly.
1,700
completed projects
85%
repeat business
88%
positive recommendation
Let us help you conduct your next trial 🏥
© 2024 Optimapharm All rights reserved.
